ArticleExperimental diabetes research2008
Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats.
Article in Experimental diabetes research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02911792 (Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration), which is not on this map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
Who cites it
37 citing papers in PubMed, 103 citations in OpenAlex.
- The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.Diabetologia · 2016Trial
- Comprehensive review on ethnobotanical, nutritional and functional properties of wild edible fruits of North Eastern Himalaya, India.Journal of food science and technology · 2025Review
- Losartan is more effective than angiotensin (1-7) in preventing thyroxine-induced renal injury in the rat.Thyroid research · 2024Article
- Maternal dexamethasone exposure does not affect glucose tolerance but alters renal haemodynamics in FEndocrinology, diabetes & metabolism · 2023Article
- The assessment of cortical hemodynamic responses induced by tubuloglomerular feedback using in vivo imaging.Physiological reports · 2023Article
- Bioactive Substances and Biological Functions inMolecules (Basel, Switzerland) · 2023Review
- The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model.Stem cell research & therapy · 2022Article
- Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.Nephrology (Carlton, Vic.) · 2021Review
- Hyperpolarized magnetic resonance shows that the anti-ischemic drug meldonium leads to increased flux through pyruvate dehydrogenase in vivo resulting in improved post-ischemic function in the diabetic heart.NMR in biomedicine · 2021Article
- L-Carnitine Stimulates In Vivo Carbohydrate Metabolism in the Type 1 Diabetic Heart as Demonstrated by Hyperpolarized MRI.Metabolites · 2021Article
- Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model.Physiological research · 2021Article
- The Bioavailability, Extraction, Biosynthesis and Distribution of Natural Dihydrochalcone: Phloridzin.International journal of molecular sciences · 2021Review
- Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.Transplant international : official journal of the European Society for Organ Transplantation · 2021Review
- Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development.Journal of the American Heart Association · 2020Review
- A treatment with a boiled aqueous extract of Hancornia speciosa Gomes leaves improves the metabolic status of streptozotocin-induced diabetic rats.BMC complementary medicine and therapies · 2020Article
- Effect ofEXCLI journal · 2020Article
- Histological and biochemical effects of Cinnamomum cassia nanoparticles in kidneys of diabetic Sprague-Dawley rats.Bosnian journal of basic medical sciences · 2019Article
- Calcium Dobesilate Restores Autophagy by Inhibiting the VEGF/PI3K/AKT/mTOR Signaling Pathway.Frontiers in pharmacology · 2019Article
- The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors.Internal medicine (Tokyo, Japan) · 2018Review
- SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationships of renal and glomerular hypertrophies to development of hyperfiltration and proteinuria early in streptozotocin-induced diabetes were explored. Control, diabetic, phlorizin-treated controls, and diabetic male Fischer rats were used. Phlorizin (an Na+-glucose cotransport inhibitor) was given at a dose sufficient to normalize blood glucose. Inulin clearance (C(inulin)) and protein excretion rate (PER) were measured. For morphometry, kidney sections were stained with periodic acid Schiff. At one week, diabetes PER increased 2.8-folds (P < .001), C(inulin) increased 80% (P < .01). Kidney wet and dry weights increased 10%-12% (P < .05), and glomerular tuft area increased 9.3% (P < .001). Phlorizin prevented proteinuria, hyperfiltration, and kidney hypertrophy, but not glomerular hypertrophy. Thus, hyperfiltration, proteinuria, and whole kidney hypertrophy were related to hyperglycemia but not to glomerular growth. Diabetic glomerular hypertrophy constitutes an early event in the progression of glomerular pathology which occurs in the absence of mesangial expansion and persists even after changes in protein excretion and GFR are reversed through glycemic control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.